(Total Views: 118)
Posted On: 07/05/2017 9:58:16 AM
Post# of 72447
I post the FINRA daily short numbers only on stocks I am invested in that imho are under attack. Those short hate having this information posted as it shines light on how they are attacking the company and trying to bankrupt the company and steal investors hard earned savings in the process. Thankfully our management is savvy and has been fighting back against the attackers for years. I am proud of them and respect their efforts as an investor. I look forward to being part of a group of investors that turns the tables on these SOB's. and I am confidant that happening is not far away. Notices like the following cause me to continue to invest what I am able as funds are available rather than scare me away. Proud to be an IPIX investor. Go IPIX!!!
Special Alert from CEO
View it in your browser.
My Fellow Cellceutix Shareholders,
Many investors are aware that when a company announces plans to uplist to a senior exchange, they attract and become vulnerable to those engaged in short selling. These people/funds take short positions trying to drive a stock down and hope for a reverse split to be necessary to meet share price requirements for the senior exchange. The companies are viewed as easy prey, as often these companies need to uplist in order to meet conditions of a financing.
We’re not splitting our stock. We have cash on hand and an equity line. Long term shareholders know we’ve been through these short attacks before and each time the stock recovered and reached new highs. As far as the uplist, it is in progress with NASDAQ.
If one has doubt as to the potential of our lead anti-cancer drug Kevetrin, I encourage you to read this morning’s press release disclosing that the Institutional Review Board (IRB) approved additional enrollment for our trial of Kevetrin for solid tumors at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Typically, we are not inclined to release news on Fridays, but we wanted to share this – what we consider to be fantastic – news immediately with our shareholders.
Understand that Harvard Cancer Centers sit among the elite in the country for cancer research. The Scientific Review Committee and IRB had no obligation to allow for additional enrollment in our trial. After treating forty patients, would they want to treat more patients with a drug candidate that they don’t believe has potential? Of course not. We interpret the IRB approval as a strong vote of confidence as to the safety and potential impact of Kevetrin.
Thank you for your continued support.
Sincerely,
Leo Ehrlich, Chief Executive Officer, Cellceutix
Copyright © 2015 Cellceutix Corporation, All rights reserved.
You requested to receive email alerts about Cellceutix at our website www.cellceutix.com
Our mailing address is:
Cellceutix Corporation
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Add us to your address book
Email Marketing Powered by MailChimp
unsubscribe from this list | update subscription preferences
Special Alert from CEO
View it in your browser.
My Fellow Cellceutix Shareholders,
Many investors are aware that when a company announces plans to uplist to a senior exchange, they attract and become vulnerable to those engaged in short selling. These people/funds take short positions trying to drive a stock down and hope for a reverse split to be necessary to meet share price requirements for the senior exchange. The companies are viewed as easy prey, as often these companies need to uplist in order to meet conditions of a financing.
We’re not splitting our stock. We have cash on hand and an equity line. Long term shareholders know we’ve been through these short attacks before and each time the stock recovered and reached new highs. As far as the uplist, it is in progress with NASDAQ.
If one has doubt as to the potential of our lead anti-cancer drug Kevetrin, I encourage you to read this morning’s press release disclosing that the Institutional Review Board (IRB) approved additional enrollment for our trial of Kevetrin for solid tumors at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Typically, we are not inclined to release news on Fridays, but we wanted to share this – what we consider to be fantastic – news immediately with our shareholders.
Understand that Harvard Cancer Centers sit among the elite in the country for cancer research. The Scientific Review Committee and IRB had no obligation to allow for additional enrollment in our trial. After treating forty patients, would they want to treat more patients with a drug candidate that they don’t believe has potential? Of course not. We interpret the IRB approval as a strong vote of confidence as to the safety and potential impact of Kevetrin.
Thank you for your continued support.
Sincerely,
Leo Ehrlich, Chief Executive Officer, Cellceutix
Copyright © 2015 Cellceutix Corporation, All rights reserved.
You requested to receive email alerts about Cellceutix at our website www.cellceutix.com
Our mailing address is:
Cellceutix Corporation
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Add us to your address book
Email Marketing Powered by MailChimp
unsubscribe from this list | update subscription preferences
(3)
(0)
